프론트바이오 - 로고

Eczema Therapeutics

  • R&D
  • Eczema Therapeutics

What is eczema?

Dermatitis

Eczema

  • Erythema

  • water blister

  • tissue detachment

  • Irritable inflammatory skin disease
  • Symptoms of itching, erythema, blisters,
    tissue detachment, etc.
  • It belongs to intractable diseases that are easy to recurrence

Properties of new drug for Eczema

  • Medical Unmet Need

    • Most prescriptions are steroid ointments.
    • High efficacy drug with no side effect
    • Low recurrence rate
  • Problems of existing treatments

    • Risks of causing newborn malformation for current drug
    • Current drug was approved as a second-line therapy for chronic severe hand eczema in adults who do not respond to strong topical steroid therapy for at least 4 weeks.
    • Due to safety concerns, it can only be administered for up to 24 weeks.
    • Low efficacy (45%) with high recurrence

Characteristics of
the target drugs

  • Excellent efficacy in short treatment time
  • Established safety and no side effects with natural ingredients
  • Oral administration
  • The mechanism of action is suppressing the abnormal immune responses.

Competitiveness of the FB718A1

Animal efficacy experiment Suppression of
"Itching, swelling, erythema, scale, epidermal peeling, skin thickness"

  • Itching

  • swelling

  • erythema

  • scale

  • epidermal peeling

  • skin thickness

Mechanism of Action for FB718A1

  • Confirmation of maintaining balance
    of Th1 / Th2 related cytokines
  • Animal experiments
    for efficacy and MoA

Important biomarkers of eczema were improved.
“decreased levels of IgE, IL-4, IL-10 and increased level of IFN-γ in serum”

Competitiveness of the FB718A1

Eczema treatment
FB718A1

  • Specialty

    Identification of MoA

    Identification of
    mechanisms
    related to
    immune function

    Safe natural drug

    Safety confirmed by
    preclinical trials

    Oral treatment

    Convenient administration

    No side effects

    Excellent efficacy and
    rapid treatment effect

    Higher than 90%
    therapeutic effect after
    3 weeks of administration

  • Marketability

    Big Market Size

    Present: $4.88 billion
    2022: $5.63 billion

  • Monopoly

    Secured intellectual
    property rights

    Domestic patent
    registration completed
    Completed 5 overseas applications

    (Securing global rights)